4-Heteroarylimidazo-[1,5-A]pyrimidines

Abstract

Novel pyrimidine compounds are disclosed of the class represented by the formula: ##STR1## wherein R.sub.1 is selected from the class consisting essentially of hydrogen, chloro, bromo, cyano (--CN), carbamoyl (--CO--NH.sub.2), carboxyl (--COOH), and lower alkoxycarbonyl (--CO--O--R.sub.3, where R.sub.3 is a lower alkyl radical having 1-4 carbon atoms), and wherein R.sub.2 is a monovalent radical selected from the class consisting essentially of furyl, thienyl, 3-pyridyl and 3-pyridyl-N-oxide, either of said pyridyl radicals optionally being substituted with an alkyl radical having from 1 to 4 carbon atoms. Processes of preparing such compounds are disclosed. The novel compounds are useful as anxiolytic agents in ameliorating anxiety in a mammal.

Dependencies are inferred from the claim text.